Caroline Caperton, MD, MSPH

02/04/2026

Pensacola doctors are reporting the first measles case in Escambia County in 20 years. See link below ⬇️ bit.ly/4c5RVp5

02/04/2026

South Carolina measles outbreak hits 876 with 29 new cases

Among confirmed cases, 800 case-patients are unvaccinated against measles.

https://www.cidrap.umn.edu/south-carolina-measles-outbreak-hits-876-29-new-cases

02/04/2026

The FDA has issued a Complete Response Letter for Anaphylm™, a dissolvable orally delivered epinephrine film developed by Aquestive Therapeutics, citing concerns related to usability rather than effectiveness.
Importantly, the FDA did not request new studies on Anaphylm’s efficacy or overall safety. Instead, it is requiring additional human-factors and usability validation studies.
Aquestive plans to complete these studies and resubmit its application in Q3 2026, requesting a rapid review.
Epinephrine remains the first-line treatment for anaphylaxis. Regulatory decisions like this underscore the importance of not only developing effective treatments but also ensuring they can be used quickly, correctly, and confidently when seconds matter.
FARE supports continued innovation and remains hopeful as the FDA and Aquestive Therapeutics work through the next steps for the benefit of the food allergy community.

02/01/2026

The AAP’s recommended pacing of childhood vaccines considers when children are most likely to be exposed to contagious diseases and when children’s immune systems will respond best. This timing has kept millions of kids healthy, so they can focus on growing, playing, and learning.

Our recommendations are based on decades of research and the expertise of pediatricians and public health professionals. Learn more about AAP's 2026 immunization schedule: https://bit.ly/2TPNAkc

01/26/2026

The WK Allergy, Asthma and Immunology Center will remain CLOSED until Wednesday, January 28, 2026 due to the ice on the roads.

We are grateful to Willis Knighton Health admin & the dedicated service teams providing excellent care & leadership during this ice storm.

Willis Knighton hospitals will continue to care for inpatients and those coming to the emergency department for serious medical conditions. However, all clinics will remain closed until Wednesday, including Physicians Network offices as well as all Quick Care and Work Kare locations. Surgical Services will continue for emergency conditions, but closed for elective surgeries.

Willis Knighton is grateful for the many employees who have stayed overnight in the hospitals to ensure that patient care is uninterrupted.

01/25/2026

Due to inclement weather,
WK ALLERGY CLINIC is CLOSED on MONDAY & TUESDAY, Jan. 26-27, 2026.

IF YOU HAVE AN APPOINTMENT SCHEDULED ON Wednesday 1/28|26 or plan to come for allergy shots or oral immunotherapy, PLEASE CALL THE CLINIC BEFORE COMING TO ENSURE WE ARE OPEN! We do plan on being open and available Wednesday morning at 8 AM unless anything else crazy happens. 🤪❄️

Thank you for your understanding, and we hope everyone stays safe & warm!

01/23/2026

Due to inclement weather,
WK ALLERGY CLINIC is CLOSED on MONDAY, Jan. 26, 2026.

Admin will assess & advise regarding Tuesday, Jan. 27.
For updates regarding Tuesday & the rest of next week, please check back on our page here.

IF YOU HAVE AN APPOINTMENT SCHEDULED ON TUESDAY 1/27|26 or plan to come for allergy shots or oral immunotherapy, PLEASE CALL THE CLINIC BEFORE COMING TO ENSURE WE ARE OPEN!

Thank you for your understanding, and we hope everyone stays safe & warm!

01/23/2026

01/15/2026

AAAAI celebrates the addition of training on “best practices to prevent, recognize and respond to food-related allergic reactions” for federal school lunch and breakfast programs from today’s signing of the Whole Milk for Healthy Kids Act.

01/10/2026

01/10/2026

The AAFP rigorously reviews the science so we can support family physicians in protecting patients through safe, effective vaccination. You can count on the AAFP childhood immunization schedule: https://bit.ly/46HPsgq

12/21/2025

Recent research explores a new vaccine for food allergy management. A novel approach called the IgE-K vaccine is showing significant promise in early preclinical studies, with the potential to offer long-lasting protection from anaphylaxis with infrequent dosing if it proves effective in humans. IgE is the central antibody that drives allergic reactions, and IgE-K works by training the immune system to block IgE before it can bind to the immune cells responsible for triggering severe symptoms. In early research, the vaccine prompted the body to generate durable blocking antibodies that neutralize IgE and prevent the activation of these reaction-initiating cells. The results have been encouraging, with humanized mice demonstrating protection for up to a year following treatment. While further research is needed, this development represents a potentially transformative step forward. Advances like this underscore the momentum in food allergy science, and the growing hope for safer, more effective solutions. Read more here: https://bit.ly/4q9Ggta